← boardnext 2028-09next 2029-05
FTH
Faeth Therapeuticsdistress 2/10 · well-funded / low risk$28.40-1%today-21% from 52w high
Lead: HR+ HER2- Breast Cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$293M
Runway
12.2 yrs
Shares 1y
+6%
Price & events
+150.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
+9.5%
1W
+18.3%
1M
-12.9%
3M
+169.2%
6M
+300.0%
1Y
+115.8%
2Y
-81.0%
5Y
-92.5%
All
Overview
- Market Cap
- $38.11M
- Volume
- 23.23K
- 52 Week Range
- $6.80 – $36.16
- Total Shares
- 1.34M
- Float Shares
- 1.17M
- Short %
- 3.07%
- % Held by Insiders
- 1.45%
- % Held by Institutions
- 25.67%
- RVOL
- 0.12x
- Beta
- -0.26
Pipeline stages · 2 programs
Sapanisertib, Serabelisib, Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Serabelisib, Sapanisertib, Fulvestrant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-09 Estimated 50% readout ~2028-10-16 | Phase 2 | Sapanisertib, Serabelisib, Paclitaxel | Endometrial Cancer | — | recruiting |
| 2029-05 Estimated 50% readout ~2029-06-15 | Phase 1/2 | Serabelisib, Sapanisertib, Fulvestrant | HR+ HER2- Breast Cancer | — | recruiting |
Catalyst news & presentations · 4
- 2026Guided 40%trial initiationsecondaryPhase 2solnerstotug · Planned Phase 2 studies subject to FDA feedback and capital.SEC 8-K
- 2026-06-10withdrawalTerminated Sales Agreement with Jefferies; no shares sold.SEC 8-K
- Q1 2026trial initiationsecondaryPhase 2solnerstotug · Initiate Phase 2 study subject to funding.SEC 8-K
- Monday October 20th at 8:00 AM ETconferencedata presentationsecondarysolnerstotug · Investor webcast to discuss clinical results.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $55 (+92% upside) · 6 analysts
- 2026-07-20CitizensMarket Outperform
- 2026-07-16BTIGBuy
- 2026-06-26BairdOutperform
- 2026-06-22HC Wainwright & Co.Buy
- 2026-06-15BTIGBuy
- 2026-06-11BTIGBuy
Competitors — HR+ HER2- Breast Cancer
- none identified
Recent news
- 2026-07-20FTH Initiated Coverage by Citizens -- Price Target Announced at $51 - GuruFocus
- 2026-07-20FTH Initiated Coverage by Citizens -- Price Target Announced at $51 - GuruFocus
- 2026-07-20Faeth Therapeutics initiated with an Outperform at Citizens - TipRanks
- 2026-07-16Issuance/retirement of debt (net) of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
- 2026-07-15Faeth Therapeutics, Inc trading resumes - TipRanks
- 2026-07-15A Closer Look At Faeth Therapeutics' PIKTOR - RTTNews
- 2026-07-03Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
- 2026-07-02Faeth Therapeutics CFO Stephenson buys $326,127 in FTH stock - Investing.com India
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.